Strategies to extend the tumor-suppressive functions of canonical pathway activation in stroma, either through activation of the positive regulators of Hh ligands or agonism of downstream targets such as BMPs [74], may be best in early-stage cancers as the tumor-suppressive effects of stromal pathway activation are most potent in early tumorigenesis. This evidence concerns the gene CLN5 and cancer.